Tazobac(2 gm+0.25 gm)/vial

Tazobac is an injectable combination antibiotic (an extended-spectrum penicillin plus a beta-lactamase inhibitor) used to treat serious bacterial infections caused by susceptible, including beta-lactamase-producing, organisms.

Established / FDA-approved uses

• Complicated intra-abdominal infections (e.g. appendicitis with peritonitis, peritonitis), typically with an antibacterial active against anaerobes when clinically indicated
• Complicated and uncomplicated skin and skin structure infections, including diabetic foot infections
• Community-acquired pneumonia (moderate severity)
• Nosocomial (hospital-acquired) pneumonia, moderate to severe, generally used together with an aminoglycoside
• Postpartum endometritis and other pelvic infections

Guideline-supported / adjunct uses

• Empiric therapy of febrile neutropenia, usually in combination with an aminoglycoside, as recommended by infectious disease guidelines
• Empiric broad-spectrum coverage in sepsis of unknown source pending culture results, per local antibiogram and specialist guidance

The final choice of antibiotic and duration of therapy should be guided by culture and sensitivity results and a physician's clinical judgment.

Each vial for injection contains Piperacillin + Tazobactam in a fixed ratio of 8:1 (piperacillin sodium equivalent to piperacillin, and tazobactam sodium equivalent to tazobactam). Common strengths include 2.25 g (2 g piperacillin/0.25 g tazobactam), 3.375 g (3 g/0.375 g), and 4.5 g (4 g/0.5 g) per vial for reconstitution as an intravenous infusion.

Tazobac combines piperacillin, an extended-spectrum (ureidopenicillin) antibiotic, with tazobactam, a beta-lactamase inhibitor. Tazobactam itself has little intrinsic antibacterial activity but protects piperacillin from breakdown by many bacterial beta-lactamase enzymes, thereby extending piperacillin's spectrum of activity to include many otherwise-resistant Gram-positive, Gram-negative, and anaerobic organisms, including Pseudomonas aeruginosa.

Tazobac is supplied as a sterile powder for reconstitution and is administered only as an intravenous infusion under medical supervision, typically in a hospital or clinic setting.

Tazobac belongs to the beta-lactam antibiotic class, specifically an extended-spectrum (ureidopenicillin) penicillin combined with a beta-lactamase inhibitor.

Piperacillin + Tazobactam is bactericidal. Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death of actively dividing bacteria. Tazobactam is a suicide inhibitor of many bacterial beta-lactamase enzymes (including many plasmid-mediated and some chromosomal enzymes); it binds irreversibly to these enzymes, preventing them from inactivating piperacillin, and thereby restores piperacillin's activity against many beta-lactamase-producing strains.

After intravenous infusion, both components are widely distributed into tissues and body fluids and are primarily eliminated renally, largely unchanged, via glomerular filtration and tubular secretion. Elimination half-life is prolonged in renal impairment, requiring dose adjustment.

Tazobac must be reconstituted and further diluted as directed, then administered as an intravenous infusion (commonly over 30 minutes, or as an extended infusion where prescribed) by a healthcare professional. It must not be given intramuscularly, and must not be mixed in the same infusion line or container as an aminoglycoside antibiotic (see Interactions). It should not be self-administered at home without direct medical supervision.

Tazobac has the following clinically significant interactions:

• Probenecid: reduces renal tubular secretion of piperacillin, increasing and prolonging its blood levels; concurrent use is generally avoided unless intended by the prescriber.
• Methotrexate: Tazobac can reduce renal clearance of methotrexate, increasing the risk of methotrexate toxicity; methotrexate levels should be monitored if co-administered.
• Oral anticoagulants (e.g. warfarin) and heparin: Tazobac may enhance anticoagulant effect (via effects on platelet aggregation and gut vitamin-K-producing flora); increased bleeding risk and more frequent coagulation monitoring may be needed.
• Aminoglycosides: physically and chemically incompatible with Tazobac when mixed in the same IV line, solution, or syringe (piperacillin can inactivate aminoglycosides in vitro); the two must be infused separately, through different lines or with adequate flushing between infusions.
• Neuromuscular blocking agents (e.g. vecuronium): Tazobac may prolong the duration of neuromuscular blockade; caution is needed during and after anesthesia.

Inform your physician of all other medicines you are taking before starting Tazobac.

Most people tolerate Tazobac well, but side effects can occur.

Common

• Diarrhea, nausea, vomiting, constipation
• Headache, insomnia
• Rash, itching
• Injection/infusion site reactions
• Mildly elevated liver enzymes

Less common but important

• Hypersensitivity reactions, including rash, fever, and rarely anaphylaxis (see Contraindications)
• Electrolyte disturbances, particularly low potassium (hypokalemia), related to the sodium content of the formulation
• Clostridioides difficile-associated diarrhea/colitis, which can range from mild to severe and may occur even after the medicine is stopped
• Blood count changes (e.g. low white cell or platelet counts)

Seek prompt medical attention for severe rash, difficulty breathing, swelling of the face/throat, severe or persistent diarrhea, or unusual bleeding/bruising.

Pregnancy: Penicillin-class antibiotics such as Tazobac are generally considered among the lower-risk antibiotic options in pregnancy, but adequate, well-controlled human studies are limited. Tazobac should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only as prescribed by a physician.

Lactation: Piperacillin passes into breast milk in small amounts. Tazobac should be used during breastfeeding only under medical supervision, with the infant monitored for possible effects such as diarrhea or thrush; consult your physician before use.

Before receiving Tazobac, tell your physician about any history of allergy to penicillins, cephalosporins, or other drugs; kidney disease; bleeding disorders; a low-sodium diet or heart failure (the formulation contains sodium); or any gastrointestinal disease, particularly prior colitis.

• Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi; monitor for secondary infection.
• Watch for signs of severe or persistent diarrhea during or after treatment, which may indicate C. difficile-associated colitis (see Side Effects).
• Periodic monitoring of renal function, liver function, and electrolytes (especially potassium) is recommended during prolonged therapy.
• Use with caution in patients with bleeding tendencies, as high doses of penicillins have been associated with abnormal bleeding.

Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose of Tazobac may cause neuromuscular excitability or seizures, particularly in patients with renal impairment, along with exaggerated side effects such as nausea, vomiting, and diarrhea. If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive; both piperacillin and tazobactam can be removed by hemodialysis if needed.

Store unreconstituted vials at room temperature (below 30°C), protected from light and moisture. Once reconstituted or diluted for infusion, use within the time and storage conditions (including refrigeration) specified by the manufacturer/pharmacist, as reconstituted solutions have limited stability. Keep out of reach of children.

Renal impairment

Dose and dosing interval of Tazobac must be reduced according to creatinine clearance; patients on hemodialysis need a supplemental dose after each dialysis session. Consult a physician for individualized dosing.

Hepatic impairment

No routine dose adjustment is generally required for hepatic impairment alone, but patients with combined hepatic and renal impairment should be monitored closely.

Elderly

Dose adjustment is based on renal function rather than age alone; elderly patients often have reduced renal function and may need lower doses.

Pediatric and pregnant/breastfeeding patients

See Pediatric Uses and Pregnancy and Lactation sections.

Duration of treatment with Tazobac depends on the type and severity of infection and clinical response, and is determined by the treating physician — commonly ranging from about 5 to 14 days, with some infections (e.g. nosocomial pneumonia) treated for longer. Complete the full prescribed course even if symptoms improve earlier, unless your physician advises otherwise.

Tazobac powder for injection must be reconstituted by a healthcare professional using an appropriate diluent (e.g. Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose, per the manufacturer's instructions), then further diluted if required before intravenous infusion. Reconstituted solutions should be inspected for particulate matter and discoloration before use, and used within the manufacturer-specified time when stored at room temperature or under refrigeration. Do not mix or co-infuse with aminoglycosides in the same line or container (see Interactions).

Beta-lactam antibiotic – extended-spectrum (ureidopenicillin) penicillin combined with a beta-lactamase inhibitor.

Piperacillin + Tazobactam works through the combined action of its two components: piperacillin binds to penicillin-binding proteins in the bacterial cell wall, inhibiting cell wall synthesis and causing bacterial cell lysis (bactericidal action). Tazobactam inactivates many bacterial beta-lactamase enzymes that would otherwise destroy piperacillin, protecting it and extending its activity against beta-lactamase-producing, otherwise-resistant bacteria.

B (FDA legacy pregnancy category)

Tazobac may be used in pediatric patients (commonly from about 2–9 months of age and older, per approved labeling) for appropriate indications such as complicated appendicitis/peritonitis, using weight-based intravenous dosing determined by a pediatrician, adjusted for age and renal function.

Safety and efficacy in neonates and very young infants below the studied age range have not been well established, and use in this group should be limited to situations where a pediatric specialist judges the benefit clearly outweighs the risk, with close monitoring.